Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01350895
Recruitment Status :
First Posted : May 10, 2011
Last Update Posted : November 6, 2013
Taipei Medical University WanFang Hospital
Information provided by (Responsible Party):
Ming-I Hsu, Taipei Medical University WanFang Hospital
To study the clinical and biochemical characteristics women with polycystic ovary syndrome (PCOS) in different aged groups.
Condition or disease
Polycystic Ovary Syndrome
Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder of reproductive age women, affecting an estimated 9-18% of all women in this age group. To diagnose of PCOS in early life is especially important because it is now thought to increase metabolic and cardiovascular risks. Investigating PCOS is crucial as it is now considered to increase metabolic and cardiovascular risk, thereby impacting the health of women to a much greater extent than previously thought. We are plan using retrospective analysis to evaluate the clinical and biochemical presentation of PCOS in different aged groups.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 46 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Reproductive age women
Reproductive age women with sufficient data
Disorders of uterus (e.g. Asherman's Syndrome, Mullerian agenesis) and chromosomal anomalies (e.g. Turner syndrome)
women who had had menarche at less than 3 years of age, Day 3 FSH > 15, or who were older than 46
women with inadequate clinical/biochemical records
and women who had had ovarian cysts or ovarian tumors in ultrasonography examination